Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
50 participants
INTERVENTIONAL
2015-07-31
2019-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell lung cancer, hepatocellular carcinoma, ovarian cancer, mantle-cell lymphoma, and glioblastoma, this regimen will be chosen for the first dose to be evaluated in the phase Ib. Based on a 3 + 3 modified Fibonacci design, the tolerable dose of palbociclib for the phase IIa is defined.
* Phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest. Based on the optimal two-stage design of Simon, 21 patients are treated in the first stage. If results are positive, 29 additional patients will be recruited into the second stage of the study. An efficacy of the investigational therapy will be rejected in the first stage of 21 treated patients if two or less patients achieve complete remission (CR), CR with incomplete blood count recovery (CRi), partial remission (PR), or anti-leukemic effect (ALE). If three or more patients achieve CR, CRi, PR, or ALE during this first stage, the trial is intended to be continued in the second stage with a total sample size of 50 patients.
Start of recruitment: July 2015 End of recruitment: July 2017 End of study (last patient out): July 2018 The treatment duration of an individual patient is estimated to be 2-6 months, but may be unlimited in patients with sustained response ("case-by-case decision").
Observation time per patient after entry into the study (incl. treatment) is at least 12 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
NCT00003230
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
NCT03132454
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01142427
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
NCT01361334
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
NCT03844997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Palbociclib
Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.
phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest.
Palbociclib
oral, once daily (125mg, 100mg or 75mg) for 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palbociclib
oral, once daily (125mg, 100mg or 75mg) for 21 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with MLL-rearranged leukemia who are refractory to standard induction therapy and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)
* Patients with MLL-rearranged leukemia who relapsed after standard first-line treatment and are not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)
* Patients with newly diagnosed MLL-rearranged leukemia who are not eligible for intensive first-line therapy
* Genetic/histologic/immunohistologic assessment in one of the central laboratories
* Age ≥ 18 years, no upper age limit
* WHO performance status of ≤ 2
* No prior chemotherapy two weeks before study entry except hydroxyurea to control hyperleukocytosis
* Non-pregnant and non-nursing. Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (WOCBP is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 months).
* Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for three months after the last dose of therapy.
* Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.
* Men must agree not to father a child and must use a latex condom during any sexual contact with WOCBP while receiving therapy and for three months after therapy is stopped, even if they have undergone successful vasectomy.
* Signed written informed consent
Exclusion Criteria
* Performance status \> 2 according to WHO criteria
* Organ insufficiency: creatinine \> 1.5 x upper normal serum level; bilirubin, AST, or AP \> 2.5 x upper normal serum level; heart failure NYHA III/IV; uncontrolled hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or restrictive ventilation disorder
* Uncontrolled infection
* Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
* Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
* Known or suspected active alcohol or drug abuse
* Known positivity for HIV, active HAV, HBV, or HCV infection
* Bleeding disorder unrelated to leukemia
* Uncontrolled CNS involvement (treatment for CNS-involvement prior to inclusion is allowed)
* QTc \> 470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes
* Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
* No consent for registration, storage, and processing of individual disease characteristics, information on the course of the disease, and information obtained from the family physician and/or other physicians involved in the treatment of the patient about study participation
* No consent for biobanking
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
National Center for Tumor Diseases, Heidelberg
OTHER
University of Ulm
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Paschka
Prof. Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinikum Augsburg
Augsburg, , Germany
Helios Klinikum Bad Saarow
Bad Saarow, , Germany
Charité Campus Benjamin Franklin
Berlin, , Germany
Vivantes Klinikum Neukölln
Berlin, , Germany
Charité Campus Virchow-Klinikum
Berlin, , Germany
Universitätsklinikum Bonn
Bonn, , Germany
Städtisches Klinikum Braunschweig gGmbH
Braunschweig, , Germany
Universitätsklinikum Düsseldorf
Düsseldorf, , Germany
Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH
Essen, , Germany
Malteser Krankenhaus St. Franziskus-Hospital
Flensburg, , Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, , Germany
MVZ Osthessen
Fulda, , Germany
Universitätsklinikum Giessen
Giessen, , Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Universitätsklinikum Heidelberg
Heidelberg, , Germany
Städtisches Klinikum Karlsruhe gGmbH
Karlsruhe, , Germany
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, , Germany
Caritas-Krankenhaus Lebach
Lebach, , Germany
Uni-Klinikum der Otto-von-Guericke-Universität
Magdeburg, , Germany
Universitätsmedizin der Johannes Gutenberg-Universität
Mainz, , Germany
Pius Hospital Oldenburg
Oldenburg, , Germany
Medizinische Universitätsklinik Tübingen
Tübingen, , Germany
University Hospital of Ulm
Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMLSG 23-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.